At a current market capitalisation of approximately A$150 million , Paradigm Biopharmaceuticals appears materially undervalued when compared to peers advancing osteoarthritis (OA) disease modifying therapies, particularly Kolon TissueGene , whose valuation translates to ~A$55 per share at today’s exchange rates. Kolon’s lead asset, TG‑C , is a gene modified, allogeneic cell therapy combining irradiated chondrocytes with HEK293 cells overexpressing TGF‑β1, and is currently in a global Phase 3 trial for knee OA.Read more